CoChat

THE EFFECTS OF LIPID-LOWERING AGENTS ON ACUTE RENAL ALLOGRAFT REJECTION1, 2

Kasiske, Bertram L., Heim-Duthoy, Karen L., Singer, Gary G., Watschinger, Bruno, Germain, Michael J., Bastani, Bahar · 2001 · Transplantation
Cited by 94

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Preliminary results from clinical trials suggest that 3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitors may help prevent acute renal allograft rejection. However, the mechanism for this putative effect of 3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitors, and whether it is independent of lipid-lowering per SE are unknown. METHODS: Immediately after renal transplantation we randomly allocated (proportioned 2:1:2) patients to: 1) simvastatin (10 mg/day, n=53), 2) simvastatin placebo plus gemfibrozil (dose adjusted for renal function, n=36), and 3) simvastatin placebo (n=52). RESULTS: Simvastatin, but not gemfibrozil, reduced total and low density lipoprotein cholesterol during the first 90 days posttransplant. There were no major adverse effects of therapy. However, there were no effects of treatment on acute rejection. Indeed, survival free of acute rejection at 90 days was 72% in the simvastatin group, 72% in the gemfibrozil group, and 77% in the placebo control group (P=0.771). A post hoc power analysis suggested that there was only a 7.5% chance that a true effect of simvastatin on acute rejection (versus placebo) was not detected, and a 2.5% chance that an effect of gemfibrozil on acute rejection (versus placebo) was not detected in this study. CONCLUSION: Lipid-lowering agents may not reduce the incidence of acute renal allograft rejection. However, additional studies are needed to confirm this observation. In the mean time, many if not most renal transplant recipients should be treated with HMG-CoA reductase inhibitors starting early posttransplant to prevent cardiovascular disease complications. The results of this study suggest that starting lipid-lowering therapy immediately after renal transplantation is both safe and effective in lowering total and low density lipoprotein cholesterol.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00007890-200107270-00009

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Effect of pravastatin on outcomes after cardiac transplantation

    Kobashigawa, J. A., Katznelson, S., Laks, H., Johnson, J. A., Yeatman, L., Wang, X. M., Chia, D., Terasaki, P. I., Sabad, A., Cogert, G. A., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199509073331003 · Cited by 1,301 · cited 6×

    “The acute rejection after renal transplantation is predominately a tubulointerstitial disease, and the characteristic vascular lesions seen after heart transplantation are more common and usually more severe than those seen after renal transplantation (5,6).”
    BackgroundResultInfluential
  • Simvastatin Reduces Graft Vessel Disease and Mortality After Heart Transplantation: A Four-Year Randomized Trial

    Wenke, K., Meiser, B., Thiery, J., Nagel, D., von Scheidt, W., Steinbeck, G., Seidel, D., & Reichart, B. (1997) · Circulation · doi:10.1161/01.cir.96.5.1398 · Cited by 444 · cited 5×

    “The acute rejection after renal transplantation is predominately a tubulointerstitial disease, and the characteristic vascular lesions seen after heart transplantation are more common and usually more severe than those seen after renal transplantation (5,6).”
    BackgroundInfluential

Show all 2 references

Cited by

See all 94

Metadata

Authors
Kasiske, B. L., Heim-Duthoy, K. L., Singer, G. G., Watschinger, B., Germain, M. J., & Bastani, B.
Venue
Transplantation
Published
2001-07
Volume
72
Issue
2
Pages
223-227
ISSN
0041-1337 (ISSN-L)
OpenAlex
W2037198165
Cited by
94
References
2
FWCI
5.75
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: THE EFFECTS OF LIPID-LOWERING AGENTS ON ACUTE RENAL ALLOGRAFT REJECTION1, 2. https://app.cochat.ai/papers/10.1097/00007890-200107270-00009
The paper
Kasiske, B. L., Heim-Duthoy, K. L., Singer, G. G., Watschinger, B., Germain, M. J., & Bastani, B. (2001). THE EFFECTS OF LIPID-LOWERING AGENTS ON ACUTE RENAL ALLOGRAFT REJECTION1, 2. Transplantation. https://doi.org/10.1097/00007890-200107270-00009

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.